Switch theme
Sign up to access all valuation multiples
Scandinavian ChemoTech AB is a Sweden based clinical development company. It is engaged in research on pain management and therapy for prostate cancer.
6
Last FY Revenue $0.7M
Last FY EBITDA -$1.1M
$5.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Scandinavian ChemoTech achieved revenue of $0.7M and an EBITDA of -$1.1M.
Scandinavian ChemoTech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scandinavian ChemoTech valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.7M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 73% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -160% | XXX | XXX | XXX |
| EBIT | XXX | -$1.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -195% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.4M | XXX | XXX | XXX |
| Net Margin | XXX | -209% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Scandinavian ChemoTech's stock price is SEK 2 (or $0).
Scandinavian ChemoTech has current market cap of SEK 51.4M (or $5.3M), and EV of SEK 50.4M (or $5.2M).
See Scandinavian ChemoTech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2M | $5.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Scandinavian ChemoTech has market cap of $5.3M and EV of $5.2M.
Scandinavian ChemoTech's trades at 7.7x EV/Revenue multiple, and -4.8x EV/EBITDA.
Equity research analysts estimate Scandinavian ChemoTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scandinavian ChemoTech's P/E ratio is not available.
See valuation multiples for Scandinavian ChemoTech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3M | XXX | $5.3M | XXX | XXX | XXX |
| EV (current) | $5.2M | XXX | $5.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScandinavian ChemoTech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Scandinavian ChemoTech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scandinavian ChemoTech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scandinavian ChemoTech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -160% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 268% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scandinavian ChemoTech acquired XXX companies to date.
Last acquisition by Scandinavian ChemoTech was XXXXXXXX, XXXXX XXXXX XXXXXX . Scandinavian ChemoTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Scandinavian ChemoTech headquartered? | Scandinavian ChemoTech is headquartered in Sweden. |
| How many employees does Scandinavian ChemoTech have? | As of today, Scandinavian ChemoTech has 6 employees. |
| Is Scandinavian ChemoTech publicy listed? | Yes, Scandinavian ChemoTech is a public company listed on STO. |
| What is the stock symbol of Scandinavian ChemoTech? | Scandinavian ChemoTech trades under CMOTEC B ticker. |
| When did Scandinavian ChemoTech go public? | Scandinavian ChemoTech went public in 2016. |
| Who are competitors of Scandinavian ChemoTech? | Similar companies to Scandinavian ChemoTech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scandinavian ChemoTech? | Scandinavian ChemoTech's current market cap is $5.3M |
| Is Scandinavian ChemoTech profitable? | Yes, Scandinavian ChemoTech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
